PatientSpotlight, by PanaceaIntelPatientSpotlight

Explained · Respiratory · 6 pieces

Explained

Plain-language primers - no jargon, no assumed background - for patients, caregivers, and anyone trying to understand what's actually going on.

FilterAll (75)Oncology (8)Rare Disease (8)Immunology (6)Neurology (22)Cardiometabolic (6)Respiratory (6)Women's Health (7)Mental Health (6)Ophthalmology (6)
These are written so a non-specialist can read them once and walk away with a working understanding. They are not medical advice. If you are new to the topic, the diagnosis primers are a useful place to start.

Diagnosis

4
ExplainedNEWMay 8, 2026

What is allergic bronchopulmonary aspergillosis?

Plain-language primer on ABPA, why it is different from typical asthma, and how modern therapy works.

DiagnosisTreatmentPatient journey
ExplainedNEWMay 7, 2026

Severe COPD and biologic therapy explained

Plain-language primer on severe COPD, why biologic therapy is now an option for some patients, and what the modern combined approach can offer.

DiagnosisTreatmentPatient journey
ExplainedNEWMay 5, 2026

What is obstructive sleep apnea?

Plain-language primer on obstructive sleep apnea, why CPAP has been the standard, and what is changing in OSA therapy.

DiagnosisTreatmentPatient journey
ExplainedNEWMay 4, 2026

What is refractory chronic cough?

Plain-language primer on refractory chronic cough, why it is a distinct condition, and what is changing in therapy.

DiagnosisTreatmentPatient journey

Biomarkers

1
ExplainedApr 26, 2026peer-reviewed · FDA · guideline-bodies

COPD's biomarker problem and how the field is solving it

COPD has, until recently, been managed as a single condition with a stepwise pharmacological ladder. The arrival of biologics in COPD - and the subgroup-driven trial designs that supported their approval - has forced the field to confront a biomarker question that asthma resolved a decade ago: which patient, which mechanism, which therapy, and how do we know.

CopdBiomarkersBiologicsEosinophils

Pipeline

1
ExplainedApr 26, 2026peer-reviewed · industry-filing

How chronic cough has emerged as a discrete indication with its own pipeline

Chronic cough was historically managed within the broader respiratory and ENT framework as a symptom rather than as an indication. The emergence of P2X3 receptor antagonists and adjacent novel mechanisms has established chronic cough as a discrete therapeutic indication with a distinct pipeline, regulatory pathway and commercial logic.

PipelineTreatmentDrug development